Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012

被引:21
作者
Albaum, J. M. [1 ]
Levesque, L. E. [2 ,3 ]
Gershon, A. S. [3 ,4 ]
Liu, G. [2 ,3 ]
Cadarette, S. M. [1 ,3 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] Inst Clin Evaluat Sci, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
基金
加拿大健康研究院;
关键词
Glucocorticoids; Health services research; Osteoporosis; Practice patterns; FRACTURE RISK; HIP FRACTURE; PREVENTION; PREVALENCE;
D O I
10.1007/s00198-015-3200-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We identified that glucocorticoid-induced osteoporosis management (bone mineral density testing or osteoporosis treatment) among seniors improved among men (2 to 23 %) and women (10 to 48 %) between 1996 and 2007, and then remained relatively stable through to 2012. Differences were also noted by indication (from a low of 21 % for respiratory conditions to a high of 41 % for rheumatic conditions). Purpose The aim of our study was to describe the proportion of chronic oral glucocorticoid (GC) users that receive osteoporosis management (bone mineral density test or osteoporosis treatment) by sex and over time. Methods We identified community-dwelling older adults initiating chronic oral GC therapy in Ontario using pharmacy data from 1996 to 2012. Chronic GC use was defined as greater than or equal to two oral GC prescriptions dispensed and >= 450 mg prednisone equivalent over a 6-month period. Osteoporosis management within 6 months of starting chronic GC therapy was examined by sex, year, indication for therapy, and osteoporosis management history. Results were summarized using descriptive statistics. Results We identified 72,099 men and 95,975 women starting chronic oral GC therapy (mean age = 74.9 years, SD = 6.5). Approximately two thirds of patients (65 %) received >= 900 mg within the 6-month chronic use window. GC-induced osteoporosis management increased from 2 to 23 % (men) and 10 to 48 % (women) between 1996 and 2007, and then remained relatively stable through to 2012. A higher proportion of patients with prior osteoporosis management were managed within 6 months (56 % men, 67 % women) of chronic GC use, compared to patients without prior management (12 % men, 23 % women). Patients with rheumatic disease were managed most commonly (41 %), and patients with respiratory conditions were managed least commonly (21 %). Conclusions GC-induced osteoporosis management improved significantly over time for both sexes yet remains low. Significant care gaps by sex and between clinical areas represent a missed opportunity for fracture prevention among patients requiring chronic GC therapy.
引用
收藏
页码:2845 / 2852
页数:8
相关论文
共 29 条
[1]  
Albaum JM, 2014, J POPUL THER CLIN PH, V21, pE486
[2]   Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada [J].
Benchimol, Eric I. ;
Guttmann, Astrid ;
Mack, David R. ;
Nguyen, Geoffrey C. ;
Marshall, John K. ;
Gregor, James C. ;
Wong, Jenna ;
Forster, Alan J. ;
Manuel, Douglas G. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (08) :887-896
[3]   Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage [J].
Cadarette, S. M. ;
Carney, G. ;
Baek, D. ;
Gunraj, N. ;
Paterson, J. M. ;
Dormuth, C. R. .
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (04) :1475-1480
[4]   Osteoporosis quality indicators using healthcare utilization data [J].
Cadarette, S. M. ;
Jaglal, S. B. ;
Raman-Wilms, L. ;
Beaton, D. E. ;
Paterson, J. M. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (05) :1335-1342
[5]   The burden of osteoporosis in Canada [J].
Cadarette, Suzanne M. ;
Burden, Andrea M. .
CANADIAN PHARMACISTS JOURNAL, 2011, 144 :S3-U42
[6]   Risk of mortality following clinical fractures [J].
Cauley, JA ;
Thompson, DE ;
Ensrud, KC ;
Scott, JC ;
Black, D .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) :556-561
[7]   Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients [J].
Curtis, JR ;
Westfall, AO ;
Allison, JJ ;
Becker, A ;
Casebeer, L ;
Freeman, A ;
Spettell, CM ;
Weissman, NW ;
Wilke, S ;
Saag, KG .
ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2485-2494
[8]   Fracture risk with intermittent high-dose oral glucocorticoid therapy [J].
de Vries, Frank ;
Bracke, Madelon ;
Leufkens, Hubert G. A. ;
Lammers, Jan-Willem J. ;
Cooper, Cyrus ;
van Staa, Tjeerd P. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :208-214
[9]   Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW) [J].
Diez-Perez, Adolfo ;
Hooven, Frederick H. ;
Adachi, Jonathan D. ;
Adami, Silvano ;
Anderson, Frederick A. ;
Boonen, Steven ;
Chapurlat, Roland ;
Compston, Juliet E. ;
Cooper, Cyrus ;
Delmas, Pierre ;
Greenspan, Susan L. ;
LaCroix, Andrea Z. ;
Lindsay, Robert ;
Netelenbos, J. Coen ;
Pfeilschifter, Johannes ;
Roux, Christian ;
Saag, Kenneth G. ;
Sambrook, Philip ;
Silverman, Stuart ;
Siris, Ethel S. ;
Watts, Nelson B. ;
Nika, Grigor ;
Gehlbach, Stephen H. .
BONE, 2011, 49 (03) :493-498
[10]   The population risk of fractures attributable to oral corticosteroids [J].
Donnan, PT ;
Libby, G ;
Boyter, AC ;
Thompson, P .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (03) :177-186